Investigational drug · Phase 2
HRS-5632
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Lipoprotein Disorder.
Phase 2Last checked: Nov 20, 2026Latest source record: Mar 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "HRS-5632"
First trial start
2025
Oct 21, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-5632", any sponsor or status.
Conditions studied
As listed on its trial records.
- Lipoprotein Disorder
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-5632" as an intervention, largest first.
- A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular EventsPivotal-lookingActive, not recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07185776 · 203 participants · Start Oct 21, 2025 · Primary completion Apr 2027
Drug: HRS-5632 Injection; HRS-5632 Injection Placebo · For: Lipoprotein Disorder
Sites: Xi’an, China · 2 sites in all
- A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy SubjectsCompleted
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT06732154 · 50 participants · Start Dec 2, 2024 · Primary completion Mar 2, 2026
Drug: HRS-5632; Placebo · For: Dyslipidemia
Sites: Tianjin, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Lipoprotein Disorder
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.